Age-and Gender-Related Differences in Anticoagulant Drugs Use Patterns
Journal of Pharmaceutical Research International,
Aim: Drug utilization study is considered a powerful exploratory tool to assess the present trends of drug prescribing and appropriateness of prescription and to analyze the differences in drugs utilization with respect to several factors such as age and gender. This study aims to describe the age-and gender-related differences in anticoagulant drugs use patterns.
Methodology: The present study included the review of outpatient electronic prescriptions that include an anticoagulant drug in 2018 in a public hospital in Al-karj, Saudi Arabia.
Results: Enoxaparin was prescribed mainly for patients between 20-39 years old (63.48%). Warfarin was prescribed mainly for patient more than 50 years old (59.38%). Enoxaparin was prescribed mainly for female patients (86.09%). Rivaroxaban and warfarin were prescribed mainly for female patients, 64.71% and 59.38% respectively.
Conclusion: There are differences in prescribing anticoagulant according to gender and age. It is important to know the differences in prescribing anticoagulants according to age and gender and if the treatment is inappropriate, it is important to identify and address reasons for treatment disparities in anticoagulation prescription.
- Age related
- gender related
- use patterns
How to Cite
Accessed 02 July 2020.
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1–25.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study. Lancet. 2010;380(9859): 2095-128.
Ram B, Kumar N, Ansari FA, Ahmad A, Chaudhary MK, Akhtar MDJ. Prevalence and drug utilization patterns of cardiovascular disease in a tertiary care hospital of Bihar - A Prospective and Observational Study. JMSCR. 2018;6(4): 1082-1087.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988.
Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615–621.
Hellwig T, Gulseth M. New oral therapies for the prevention and treatment of venous thromboembolism. Am J Health Syst Pharm. 2013;70(2):113–125.
Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation. 1994;89(1):432–449.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American college of chest physicians. oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl): e44S–e88S.
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2): e531S-e575S.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al. Antithrombotic therapy for VTE disease: Chest guideline and expert panel report. Chest. 2016;149(2):315-352.
Panchaksharimath P, Praveen AN, Manjunath R. A Cross-sectional study to evaluate age and gender related differences in drug utilization in ischemic heart disease at A Tertiary Care Hospital. Biomed Pharmacol J. 2018;11(4):1967-1974.
Bai Y, Guo SD, Deng H, Shantsila A, Fauchier L, Ma CS, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing. 2018;47(1):9-17.
Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J Am Geriatr Soc. 2019;67(8):1662-1671.
Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol J Cardiol. 2018; 19(1):67–71.
Abohelaika S, Wynne H, Avery P, Robinson B, Kesteven P, Kamali F. Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management. Br J Clin Pharmacol. 2016;82(4):1076–1083.
Miura T, Nishinaka T, Terada T, Yonezawa K. Relationship between aging and dosage of warfarin: the current status of warfarin anticoagulant therapy for Japanese outpatients in a department of cardiovascular medicine. J Cardiol. 2009; 53(3):355-360.
Kassim NA, Althouse AD, Qin D, Leef G, Saba S. Gender differences in management and clinical outcomes of atrial fibrillation patients. J Cardiol. 2017; 69(1):195-200.
Lee JM, Kim TH, Cha MJ, Park J, Park JK, Kang KW et al. Gender-related Differences in Management of Nonvalvular Atrial Fibrillation in an Asian Population. Korean Circ J. 2018;48(6):519–528.
Thompson LE, Maddox TM, Lei L, Grunwald GK, Bradley SM, Peterson PN et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6(7): e005801.
Grifoni E, Gori AM, Giusti B, Marcucci R. Gender differences in antithrombotic therapy. Ital J Gender-Specific Med. 2017; 3(1):15-22.
Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart. 2017;103(13):1024-1030.
Abstract View: 257 times
PDF Download: 216 times